$PLSE

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ex_1000004.htm EXHIBIT 1.1 ex_1000004.htm Exhibit 1.1 PULSE BIOSCIENCES, INC. Common Stock ($0.001 par value per share) EQUITY DISTRIBUTION AGREEMENT August 6, 2026 MIZUHO SECURITIES USA LLC 1271 Avenue of the Americas, 3 rd Floor New York, New York 10020 Ladies and Gent

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_964658.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED AUGUST 6, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS ex_964658.htm Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire

Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.

Biotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).

Pulse Clean Energy said it reached financial close on two UK battery energy storage projects in Plymouth and Dowlais, under construction. The projects received Technology Performance Insurance from Ariel Green, designed to provide up to 13 years of coverage to support financing and long-term performance risk management. Aon advised as broker and Eversheds Sutherland as legal adviser.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. plse20260607c_8k.htm false 0001625101 0001625101 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Rep

Pulse Biosciences has appointed Burke Barrett as its new CEO, with former CEO Kevin Danahy transitioning to Chief Commercial Officer. Danahy will focus on launching the recently cleared Cellfx percutaneous electrode system, a pulsed field ablation device. Barrett, who has a background in ablation device development from Cardiofocus, will lead other initiatives including bringing a cardiac ablation clamp to market, which currently requires human data for FDA clearance.

Pulse Biosciences (PLSE) filed an amended annual report (10-K/A) detailing executive compensation, board composition, and governance, including significant insider ownership. CEO Paul A. LaViolette's 2025 compensation was approximately $7.4 million, largely equity-based with performance and market-driven vesting conditions, while CFO Jon Skinner received about $2.8 million. Director Robert W. Duggan beneficially owns 71.6% of outstanding common stock, with all directors and executive officers collectively holding 74.7%, indicating highly concentrated ownership.

Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, giving her oversight of efforts to bring their nPulse Cardiac Catheter, a pulsed field ablation (PFA) device for treating atrial fibrillation, to market. Teplitsky's experience from Abbott and Zimmer Biomet is expected to be instrumental in accelerating the company's strategic priorities, including a pivotal U.S. and European trial for the device. This appointment follows Pulse Biosciences' decision to focus most of its R&D budget on the PFA device after promising first-in-human data.

This article analyzes Pulse Biosciences (PLSE) stock's performance during past market crashes to assess its risk profile. It reveals that PLSE has averaged a -34% contraction during eight major market dislocations, significantly underperforming the S&P 500's -15% drop. The analysis details PLSE's drawdowns during specific events like the 2022 Fed Tightening Inflation Bear Market (-92%) and the 2025 US Tariff Shock (-29%), concluding that such steep contractions are a baseline expectation for the stock during market shocks.